ConductScience.org, home

Paper8622019

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J and 13 others. J Clin Oncol, 1996. Cited by 1,163 papers, by iCite.

Cite this record

ConductScience Library. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Papers, record 8622019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8622019

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
1,163
iCite
Relative citation ratio, by iCite
26.6
iCite
Revised in PubMed
2026-01-28
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baselga JJ
2Tripathy DD
3Mendelsohn JJ
4Baughman SS
5Benz CCC C
6Dantis LL
7Sklarin NTN T
8Seidman ADA D
9Hudis CAC A
10Moore JJ
11Rosen PPP P
12Twaddell TT
13Henderson ICI C
14Norton LL

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Breast NeoplasmsMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Adult
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Middle Aged
Neoplasm Metastasis
Proto-Oncogene Mas

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50-CA58207NCI NIH HHSUnited StatesP50CA058207PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02758080Matching Patients With Hematologic Malignancy to Adequate Clinical TrialsBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in8622013Should we treat HER, too?https://conductscience.org/library/papers/8622013

Source PubMed

Download CSV of comments and corrections

Cited by286

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,163 citations.

PMIDTitleJournalYearIn PapersSource
41414806Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates.Cancer Res Treat2026https://conductscience.org/library/papers/41414806PubMed
40437017Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer.Sci Rep2025https://conductscience.org/library/papers/40437017PubMed
39681638PDX models for functional precision oncology and discovery science.Nat Rev Cancer2025https://conductscience.org/library/papers/39681638PubMed
39271787Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/39271787PubMed
39177768Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.Cancer Chemother Pharmacol2024https://conductscience.org/library/papers/39177768PubMed
39138287CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing.Commun Biol2024https://conductscience.org/library/papers/39138287PubMed
38911570Twenty-five years with HER2 targeted therapy.Ann Transl Med2024https://conductscience.org/library/papers/38911570PubMed
38827026Oncogenes and tumor suppressor genes: functions and roles in cancers.MedComm (2020)2024https://conductscience.org/library/papers/38827026PubMed
38355821Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).Breast Cancer Res Treat2024https://conductscience.org/library/papers/38355821PubMed
38191924Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38191924PubMed
38175349Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.Cancer Treat Res2023https://conductscience.org/library/papers/38175349PubMed
37895921The History and Development of HER2 Inhibitors.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37895921PubMed
37463446Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.J Clin Invest2023https://conductscience.org/library/papers/37463446PubMed
37280713Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.Breast Cancer Res2023https://conductscience.org/library/papers/37280713PubMed
37240498History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer.J Clin Med2023https://conductscience.org/library/papers/37240498PubMed
37174034Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37174034PubMed
36761943Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky.Front Oncol2023https://conductscience.org/library/papers/36761943PubMed
36636439Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review.JACC CardioOncol2022https://conductscience.org/library/papers/36636439PubMed
36454979The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: A piggy-back systematic review and meta-analysis.PLoS One2022https://conductscience.org/library/papers/36454979PubMed
35757801Biomaterials-Mediated Tumor Infarction Therapy.Front Bioeng Biotechnol2022https://conductscience.org/library/papers/35757801PubMed

See all 286 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8622019

GET https://conductscience.org/api/papers/v1/8622019/cited_by?page=2